| Literature DB >> 30664664 |
Pratikkumar H Vekaria1, Amar Kumar1, Dharmalingam Subramaniam2, Neil Dunavin1, Anusha Vallurupalli1, Frank Schoenen3, Siddhartha Ganguly1, Shrikant Anant2, Joseph P McGuirk1, Roy A Jensen4, Rekha Rao5,6.
1. Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Cancer Center, Kanas City, KS, USA.
2. Department of Cancer Biology, The University of Kansas Cancer Center, Kanas City, KS, USA.
3. Higuchi Biosciences Center, University of Kansas, Lawrence, KS, USA.
4. Department of Pathology & Laboratory Medicine, The University of Kansas Cancer Center, Kansas City, KS, USA.
5. Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Cancer Center, Kanas City, KS, USA. rraomanepalli@kumc.edu.
6. Department of Cancer Biology, The University of Kansas Cancer Center, Kanas City, KS, USA. rraomanepalli@kumc.edu.
Abstract
Entities:
Mesh:
Adenosine Triphosphatases/antagonists & inhibitors
Animals
Apoptosis
Autophagy
Cell Proliferation
DNA Damage/drug effects
DNA Repair/drug effects
Drug Synergism
Drug Therapy, Combination
Gene Expression Regulation, Neoplastic
Histone Deacetylase 6/antagonists & inhibitors
Histone Deacetylase Inhibitors/pharmacology
Humans
Hydroxamic Acids/pharmacology
Indoles/pharmacology
Lymphoma, Mantle-Cell/drug therapy
Lymphoma, Mantle-Cell/genetics
Lymphoma, Mantle-Cell/pathology
Mice
Mice, Inbred NOD
Mice, SCID
Nuclear Proteins/antagonists & inhibitors
Pyrimidines/pharmacology
Tumor Cells, Cultured
Xenograft Model Antitumor Assays
Substances:
CB-5083
Histone Deacetylase Inhibitors
Hydroxamic Acids
Indoles
Nuclear Proteins
Pyrimidines
HDAC6 protein, human
Histone Deacetylase 6
Adenosine Triphosphatases
p97 ATPase
ricolinostat
Year: 2019 PMID: 30664664 PMCID: PMC6730676 DOI: 10.1038/s41375-018-0355-y
Source DB: PubMed Journal: Leukemia ISSN: 0887-6924 Impact factor: 11.528